Source comparison
Tesamorelin + Ipamorelin Blend 20s Age Specific Protocol: Research Dosing Comparison
Ages 20–29 1–2mg 200–300mcg 5 days/week before sleep Amplify existing pulsatile GH release. Somatotroph responsiveness still intact Conservative dosing preserves long-term receptor sensitivity; higher doses show diminishing returns after week 4 in this age gro
This comparison does not assign a generated winner or score.
- Ages 20–29
- 1–2mg
- 200–300mcg
- 5 days/week before sleep
- Amplify existing pulsatile GH release. Somatotroph responsiveness still intact
- Conservative dosing preserves long-term receptor sensitivity; higher doses show diminishing returns after week 4 in this age group
- Ages 30–44
- 1.5–2mg
- 250–350mcg
- 5–6 days/week before sleep
- Compensate for early decline in pulse amplitude (14% per decade from age 25)
- Moderate dose increase accounts for reduced somatotroph density; still pulsed to avoid desensitization
- Ages 45+
- 2mg
- 300–500mcg
- Daily before sleep
- Restore severely blunted GH secretion in age-related decline or lipodystrophy
- Continuous dosing required due to depleted pituitary reserves; off-target effects (prolactin, cortisol) more common
- Monotherapy (Tesamorelin only)
- N/A
- Daily
- GHRH analog primes somatotrophs but lacks ghrelin-mediated release signal
- Produces 8–12 ng/mL GH peaks vs 18–24 ng/mL with ipamorelin synergy; used in clinical lipodystrophy treatment